Melanoma Clinical Trials in Pennsylvania

Showing 161-180 of 301 trials

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

NCT00003308

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy in treating patients with newly diagnosed brain metastases from kidney cancer, melanoma, or sarcoma.

Kidney CancerMelanoma (Skin)Metastatic Cancer+2 more

Eastern Cooperative Oncology GroupStarted Feb 1999

Des Moines, Iowa, United States • Des Moines, Iowa, United States • Des Moines, Iowa, United States +11 more locations

TERMINATEDPhase 336 miles

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

NCT04410445

The main purpose of this study is to compare the efficacy of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence.

MelanomaMelanoma Stage IIIMelanoma Stage IV+1 more

Nektar Therapeutics765 participantsStarted Jul 2020

Scottsdale, Arizona, United States • Little Rock, Arkansas, United States • Anaheim, California, United States +209 more locations

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence

Melanoma Trials in Other Cities

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Safety Study of SEA-CD40 in Cancer Patients

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Phase II Study of Interleukin-21 (rIL-21) vs Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

Study of ASN003 in Subjects With Advanced Solid Tumors

Other Conditions in Pennsylvania